ICON (NASDAQ:ICLR) Issues FY 2025 Earnings Guidance

ICON (NASDAQ:ICLR - Get Free Report) issued an update on its FY 2025 earnings guidance on Wednesday morning. The company provided earnings per share guidance of 13.000-14.000 for the period, compared to the consensus earnings per share estimate of 13.264. The company issued revenue guidance of $7.9 billion-$8.2 billion, compared to the consensus revenue estimate of $7.9 billion.

ICON Stock Performance

NASDAQ ICLR traded down $8.00 during trading on Friday, reaching $187.01. The company's stock had a trading volume of 1,598,447 shares, compared to its average volume of 1,571,695. The company has a current ratio of 1.29, a quick ratio of 1.29 and a debt-to-equity ratio of 0.35. The firm has a market capitalization of $15.10 billion, a price-to-earnings ratio of 19.24, a price-to-earnings-growth ratio of 2.82 and a beta of 1.17. ICON has a 12 month low of $125.10 and a 12 month high of $338.67. The firm has a 50 day moving average price of $144.57 and a 200 day moving average price of $163.41.

ICON (NASDAQ:ICLR - Get Free Report) last released its quarterly earnings data on Wednesday, July 23rd. The medical research company reported $3.26 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $3.18 by $0.08. ICON had a net margin of 9.82% and a return on equity of 10.95%. The business had revenue of $2.02 billion during the quarter, compared to analysts' expectations of $1.98 billion. During the same period in the prior year, the company earned $3.75 EPS. The firm's quarterly revenue was down 4.8% compared to the same quarter last year. As a group, equities analysts anticipate that ICON will post 13.38 EPS for the current fiscal year.

Analyst Ratings Changes

ICLR has been the topic of several research analyst reports. Barclays increased their target price on shares of ICON from $155.00 to $180.00 and gave the stock an "equal weight" rating in a research note on Friday. Evercore ISI lifted their target price on shares of ICON from $170.00 to $240.00 and gave the stock an "outperform" rating in a research note on Friday. TD Cowen lowered shares of ICON from a "buy" rating to a "hold" rating and cut their price objective for the company from $254.00 to $157.00 in a research report on Monday, April 14th. JPMorgan Chase & Co. lowered shares of ICON from an "overweight" rating to a "neutral" rating and dropped their target price for the company from $265.00 to $150.00 in a research report on Tuesday, April 29th. Finally, Mizuho lifted their target price on shares of ICON from $173.00 to $225.00 and gave the stock an "outperform" rating in a research note on Friday. Six investment analysts have rated the stock with a hold rating, nine have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $219.54.

ICON Company Profile

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.